{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:16:01Z","timestamp":1792498561574,"version":"4.5.0"},"reference-count":195,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ymgme.2018.06.004","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T11:47:05Z","timestamp":1528804025000},"page":"189-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":179,"title":["European expert consensus statement on therapeutic goals in Fabry disease"],"prefix":"10.1016","volume":"124","author":[{"given":"Christoph","family":"Wanner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Arad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Burlina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5903-3355","authenticated-orcid":false,"given":"Ulla","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor V.","family":"Fomin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique P.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6228-522X","authenticated-orcid":false,"given":"Ilkka","family":"Kantola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale\u0161","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Mignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Monserrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Namdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o-Paulo","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-9523","authenticated-orcid":false,"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pieroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tylki-Szyma\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Viana-Baptista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max J.","family":"Hilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2018.06.004_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","article-title":"Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide","volume":"109","author":"De Francesco","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0015","article-title":"Evaluation of the value of systematic reviews in rare diseases using Fabry disease as an exemplar","author":"Elliot","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0020","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease \u2013 a systematic literature review by a European panel of experts","author":"Germain","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0025","article-title":"The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease \u2013 a systematic literature review by a European panel of experts","author":"Germain","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0030","article-title":"The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease \u2013 a systematic literature review by a European panel of experts","author":"Spada","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A \u2013 replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0045","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"International Fabry Disease Study Group. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0065","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0070","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2147\/DDDT.S102761","article-title":"An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are na\u00efve to enzyme replacement therapy","volume":"10","author":"Goker-Alpan","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0075","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-6-69","article-title":"Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients","volume":"6","author":"Smid","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0080","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0085","first-page":"96","article-title":"Reduction of plasma globotriaosylsphingosine levels after switching from agalsidase alfa to agalsidase beta as enzyme replacement therapy for Fabry disease","volume":"25","author":"Goker-Alpan","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0090","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ymgme.2005.01.007","article-title":"Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry","volume":"85","author":"Kitagawa","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0095","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1651-2227.2005.tb02112.x","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2\u202fmg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0110","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","article-title":"Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy","volume":"92","author":"Ohashi","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0120","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cca.2015.06.003","article-title":"Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma","volume":"447","author":"Ferreira","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0125","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"T\u00f8ndel","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000369309","article-title":"Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria","volume":"129","author":"T\u00f8ndel","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0135","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/jhg.2016.78","article-title":"Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes","volume":"61","author":"Kim","year":"2016","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124987","article-title":"Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial","volume":"10","author":"Wijburg","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0145","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0150","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2215\/CJN.02150212","article-title":"Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988\u20132010","volume":"7","author":"T\u00f8ndel","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"T\u00f8ndel","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0160","first-page":"807","article-title":"Re-accumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients","volume":"32","author":"Skrunes","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0165","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0170","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0175","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/GIM.0b013e3181981d82","article-title":"Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease","volume":"11","author":"Lubanda","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0180","article-title":"One year of enzyme replacement therapy reduces globotriaosylceramide inclusions in podocytes in male adult patients with Fabry disease","volume":"15","author":"Najafian","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0185","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson-Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0190","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0195","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","article-title":"Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease","volume":"144","author":"Kr\u00e4mer","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0200","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1034\/j.1399-0004.2003.630107.x","article-title":"Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients","volume":"63","author":"Senechal","year":"2003","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0205","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","article-title":"Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease","volume":"96","author":"Shah","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0210","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry","volume":"57","author":"Patel","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0215","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/heartjnl-2014-306782","article-title":"Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry disease","volume":"101","author":"Patel","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0220","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0225","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0230","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"European FOS Investigators. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0235","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccep.2015.03.014","article-title":"Arrhythmias in Fabry cardiomyopathy","volume":"7","author":"Acharya","year":"2015","journal-title":"Card. Electrophysiol. Clin."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0240","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ymgme.2012.05.011","article-title":"Enzyme replacement therapy improves cardiac features and severity of Fabry disease","volume":"107","author":"Motwani","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0245","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: data from the Fabry Registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0250","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0255","first-page":"21","article-title":"Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis","volume":"3","author":"Beck","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0260","first-page":"19","article-title":"Electrical changes in resting, exercise, and Holter electrocardiography in Fabry cardiomyopathy","volume":"28","author":"Kr\u00e4mer","year":"2015","journal-title":"JMID Rep."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0265","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0270","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140627","article-title":"Left ventricular geometry and blood pressure as predictors of adverse progression of Fabry cardiomyopathy","volume":"10","author":"Kr\u00e4mer","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0280","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/08037051.2014.868629","article-title":"Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology, 2013 ESH\/ESC practice guidelines for the management of arterial hypertension","volume":"23","author":"Mancia","year":"2014","journal-title":"Blood Press."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0285","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0290","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0295","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0300","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0305","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/gim.2013.53","article-title":"Analysis of left ventricular mass in untreated men and in men treated with agalsidase-\u03b2: data from the Fabry Registry","volume":"15","author":"Germain","year":"2013","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0310","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/heartjnl-2015-308897","article-title":"The value of ECG parameters as markers of treatment response in Fabry cardiomyopathy","volume":"102","author":"Schmied","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0315","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.beem.2014.10.003","article-title":"Fabry disease and the heart","volume":"29","author":"Seydelmann","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0320","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0325","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jjcc.2007.12.001","article-title":"Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study","volume":"51","author":"Takenaka","year":"2008","journal-title":"J. Cardiol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0330","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0335","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/clc.22047","article-title":"Arrhythmias in Fabry cardiomyopathy","volume":"35","author":"Acharya","year":"2012","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0340","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2016.04.033","article-title":"Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in patients with advanced Fabry cardiomyopathy","volume":"118","author":"Weidemann","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0345","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1586\/14779072.2015.1053873","article-title":"Current applications of biomarkers in cardiomyopathies","volume":"13","author":"Coats","year":"2015","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0350","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002839","article-title":"High-sensitivity troponin: a clinical blood biomarker for staging cardiomyopathy in Fabry disease","volume":"5","author":"Seydelman","year":"2016","journal-title":"J. Am. Heart. Assoc."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0355","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment","volume":"10","author":"Kampmann","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0360","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0365","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0370","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"9","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0375","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1751-7176.2010.00271.x","article-title":"Effectiveness of an interventional program to improve blood pressure control in hypertensive patients at high risk for developing heart failure: HEROIC study","volume":"12","author":"De Rivas","year":"2010","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0380","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11906-014-0447-7","article-title":"Hypertension as a risk factor for heart failure","volume":"16","author":"Kannan","year":"2014","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0385","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0390","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0395","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2215\/CJN.03130411","article-title":"The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy","volume":"7","author":"Feriozzi","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0400","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","article-title":"Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy","volume":"52","author":"Warnock","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0405","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta","volume":"18","author":"Tahir","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0410","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0415","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0420","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/ndt\/gfp658","article-title":"Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate","volume":"25","author":"T\u00f8ndel","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0425","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0430","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0435","first-page":"1","article-title":"2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, KDIGO","year":"2013","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0440","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2215\/CJN.05570809","article-title":"Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy","volume":"5","author":"Mignani","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0445","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/ndt\/gft452","article-title":"Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease","volume":"29","author":"Prabakaran","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0450","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1681\/ASN.2013060585","article-title":"Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch","volume":"25","author":"Weidemann","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0455","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S1474-4422(12)70189-8","article-title":"Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach","volume":"11","author":"Baron","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0460","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","article-title":"Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease","volume":"121","author":"Arends","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0465","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2377-11-61","article-title":"Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel","volume":"11","author":"Burlina","year":"2011","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0470","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/cns.12542","article-title":"Pain in Fabry disease: practical recommendations for diagnosis and treatment","volume":"22","author":"Politei","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0475","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1526-4637.2008.00470.x","article-title":"Detection of a characteristic painful neuropathy in Fabry disease: a pilot study","volume":"9","author":"Maag","year":"2008","journal-title":"Pain Med."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0480","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ymgme.2012.03.010","article-title":"Small fiber neuropathy in Fabry disease","volume":"106","author":"Biegstraaten","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0485","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1529-8027.2011.00365.x","article-title":"Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy","volume":"16","author":"\u00dc\u00e7eyler","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0490","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","article-title":"Cerebrovascular involvement in Fabry disease: current status of knowledge","volume":"46","author":"Kolodny","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0495","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/arclin\/acu047","article-title":"Cognitive and psychological functioning in Fabry disease","volume":"29","author":"Sigmundsdottir","year":"2014","journal-title":"Arch. Clin. Neuropsychol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0500","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10545-013-9643-x","article-title":"Cognitive dysfunction and depression in Fabry disease: a systematic review","volume":"37","author":"Bolsover","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0505","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of FD: a study on 35 European children and adolescents","volume":"162","author":"Ries","year":"2003","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0510","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0515","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/AJP.0000000000000041","article-title":"Characterization of Pain in Fabry disease","volume":"30","author":"\u00dc\u00e7eyler","year":"2014","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0520","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10072-009-0211-y","article-title":"Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy","volume":"31","author":"Salviati","year":"2010","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0525","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0304-3959(99)00236-5","article-title":"Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients","volume":"84","author":"Hilz","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0530","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta- and Abeta-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0535","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.pain.2014.08.024","article-title":"A comprehensive Fabry-related pain questionnaire for adult patients","volume":"155","author":"\u00dc\u00e7eyler","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0540","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1477-7525-10-116","article-title":"Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)","volume":"10","author":"Ramaswami","year":"2012","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0545","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s00415-012-6619-y","article-title":"FabryScan: a screening tool for early detection of Fabry disease","volume":"259","author":"Arning","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0550","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13023-015-0325-7","article-title":"Self-administered version of the Fabry-associated pain questionnaire for adult patients","volume":"10","author":"Magg","year":"2015","journal-title":"Orphanet J. Rare. Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0555","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"Ries","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0560","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0565","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jpeds.2009.11.007","article-title":"Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease","volume":"156","author":"Schiffmann","year":"2010","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0570","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10545-014-9717-4","article-title":"Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0575","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13023-014-0169-6","article-title":"Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study","volume":"9","author":"Schiffmann","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0580","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"European Federation of Neurological Societies, EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0585","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0590","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12883-016-0549-8","article-title":"Pain management strategies for neuropathic pain in Fabry disease - a systematic review","volume":"16","author":"Schuller","year":"2016","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0595","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1213\/ANE.0000000000002500","article-title":"Opioids for the treatment of chronic pain: mistakes made, lessons learned, and future directions","volume":"125","author":"Ballantyne","year":"2017","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0600","first-page":"17","article-title":"Carpal tunnel syndrome in Fabry disease","volume":"2","author":"Ghali","year":"2012","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0605","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0610","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1651-2227.2002.tb03112.x","article-title":"Endothelial markers and homocysteine in patients with classic Fabry disease","volume":"91","author":"Demuth","year":"2002","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0615","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173358","article-title":"Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies","volume":"12","author":"El Dib","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0620","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/STR.0000000000000046","volume":"45","author":"Meschia","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0625","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0630","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000369293","article-title":"Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease","volume":"38","author":"Fellgiebel","year":"2014","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0635","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/STROKEAHA.114.008548","article-title":"Brain magnetic resonance imaging findings fail to suspect Fabry disease in young patients with an acute cerebrovascular event","volume":"46","author":"Fazekas","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0640","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1212\/WNL.0000000000002673","article-title":"Determinants of white matter hyperintensity burden in patients with Fabry disease","volume":"86","author":"Rost","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0645","doi-asserted-by":"crossref","DOI":"10.1177\/2326409814541246","article-title":"Vertebrobasilar dolichoectasia in Fabry disease: the earliest marker of neurovascular involvement?","author":"Politei","year":"2014","journal-title":"J. Inborn Errors Metab. Screen."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0650","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3174\/ajnr.A5069","article-title":"Basilar artery changes in Fabry disease","volume":"38","author":"Manara","year":"2017","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0655","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10545-010-9133-3","article-title":"Psychiatric and cognitive profile in Anderson-Fabry patients: a preliminary study","volume":"33","author":"Segal","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0660","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/WNL.0000000000001450","article-title":"Clinical prodromes of neurodegeneration in Anderson-Fabry disease","volume":"84","author":"L\u00f6hle","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0665","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137603","article-title":"Eight-year follow-up of neuropsychiatric symptoms and brain structural changes in Fabry disease","volume":"10","author":"Lelieveld","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0670","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10545-007-0708-6","article-title":"Depression in adults with Fabry disease: a common and under-diagnosed problem","volume":"30","author":"Cole","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0675","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2350-3-10","article-title":"Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients","volume":"3","author":"Germain","year":"2002","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0680","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10545-014-9783-7","article-title":"Hearing loss in adults with Fabry disease treated with enzyme replacement therapy","volume":"38","author":"Suntjens","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0685","series-title":"Fabry Disease: Perspectives from 5 years of FOS","article-title":"Fabry disease and the ear","author":"Keilmann","year":"2006"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0690","first-page":"87","article-title":"Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy","volume":"30","author":"Sergi","year":"2010","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0695","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1179\/1754762811Y0000000004","article-title":"Improved hearing with cochlear implantation in Fabry\u2019s disease","volume":"12","author":"Clinkard","year":"2011","journal-title":"Cochlear Implants Int."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0700","doi-asserted-by":"crossref","first-page":"9712831","DOI":"10.1155\/2016\/9712831","article-title":"Gastrointestinal symptoms of patients with Fabry disease","volume":"2016","author":"Pensabene","year":"2016","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0705","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-6-12","article-title":"Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study","volume":"6","author":"Kulich","year":"2008","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0710","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0715","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","article-title":"Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy","volume":"5","author":"Hoffmann","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0720","first-page":"25","article-title":"Gastrointestinal phenotype of Fabry disease in a patient with pseudoobstruction syndrome","volume":"4","author":"Buda","year":"2012","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0725","first-page":"413","article-title":"Dyspepsia in children and adolescents: a prospective study","volume":"3","author":"Hyams","year":"2000","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0730","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069876","article-title":"Gastrointestinal symptoms are still prevalent and negatively impact health-related quality of life: a large cross-sectional population based study in The Netherlands","volume":"8","author":"Tielemans","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0735","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1572-0241.2005.41893.x","article-title":"The epidemiology of childhood recurrent abdominal pain in Western countries: a systematic review","volume":"100","author":"Chitkara","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0740","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3748\/wjg.v13.i4.572","article-title":"Gastrointestinal symptoms in a Japanese population: a health diary study","volume":"13","author":"Tokuda","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0745","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.2174\/13816128113199990347","article-title":"Gastroenterological complications of Anderson-Fabry disease","volume":"19","author":"Buda","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0750","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MOG.0b013e32835bdc03","article-title":"Video capsule endoscopy of the small bowel","volume":"29","author":"Eliakim","year":"2013","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0755","first-page":"45","article-title":"Improvement of Fabry disease-related gastrointestinal symptoms in a significant proportion of female patients treated with agalsidase beta: data from the Fabry Registry","volume":"38","author":"Wilcox","year":"2017","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0760","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","article-title":"Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry","volume":"12","author":"Watt","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0765","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","article-title":"Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS\u2014the Fabry Outcome Survey","volume":"103","author":"Hughes","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0770","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1023\/B:BOLI.0000037342.59612.69","article-title":"Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease","volume":"27","author":"Dehout","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0775","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cge.12673","article-title":"Gastrointestinal involvement in Fabry disease. So important, yet often neglected","volume":"89","author":"Politei","year":"2016","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0780","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.32.5.498","article-title":"Fabry disease: impaired autonomic function","volume":"32","author":"Cable","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0785","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","article-title":"Fabry disease and the skin: data from FOS, the Fabry outcome survey","volume":"157","author":"Orteu","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0790","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1529-8027.2009.00227.x","article-title":"Autonomic skin responses in females with Fabry disease","volume":"14","author":"M\u00f8ller","year":"2009","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0795","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.autneu.2010.01.008","article-title":"Sweat production and the sympathetic skin response: improving the clinical assessment of autonomic function","volume":"155","author":"Ellaway","year":"2010","journal-title":"Auton. Neurosci."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0800","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0805","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2133.2012.10742.x","article-title":"Angiokeratoma: decision-making aid for the diagnosis of Fabry disease","volume":"166","author":"Zampetti","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0810","series-title":"Fabry Disease","first-page":"259","article-title":"Dermatological manifestations of Fabry Disease","author":"Orteu","year":"2010"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0815","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2326409816661353","article-title":"Dermatologic Aspects of Fabry Disease","volume":"4","author":"Luna","year":"2016","journal-title":"J. Inborn Errors Metab. Screen."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0820","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1076\/opge.24.3.129.15609","article-title":"Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients","volume":"24","author":"Orssaud","year":"2003","journal-title":"Ophthalmic Genet."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0825","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/bjophthalmol-2016-310088","article-title":"Conjunctival lymphangiectasia associated with classic Fabry disease","volume":"102","author":"Sivley","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0830","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/bjophthalmol-2014-306433","article-title":"Cornea verticillata supports a diagnosis of Fabry disease in non-classical phenotypes: results from the Dutch cohort and a systematic review","volume":"100","author":"van der Tol","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0835","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/bjo.2006.100602","article-title":"Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey","volume":"91","author":"Sodi","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0840","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/aos.12588","article-title":"Ophthalmic experience over 10 years in an observational nationwide Danish cohort of Fabry patients with access to enzyme replacement","volume":"93","author":"Fledelius","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0845","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/GIM.0b013e31815cb197","article-title":"Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density","volume":"9","author":"Mersebach","year":"2007","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0850","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1399-0004.2005.00457.x","article-title":"Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease","volume":"68","author":"Germain","year":"2005","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0855","first-page":"29","article-title":"Antiepileptic medications increase osteoporosis risk in male Fabry patients: bone mineral density in an Australian cohort","volume":"17","author":"Talbot","year":"2014","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0860","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10545-013-9653-8","article-title":"Potential role of vitamin D deficiency on Fabry cardiomyopathy","volume":"37","author":"Drechsler","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0865","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s10545-007-0616-9","article-title":"Natural history of the respiratory involvement in Anderson-Fabry disease","volume":"30","author":"Magage","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0870","doi-asserted-by":"crossref","DOI":"10.3402\/ecrj.v2.26721","article-title":"Fabry disease, respiratory symptoms and airway limitation \u2013 a systematic review","volume":"2","author":"Svensson","year":"2015","journal-title":"Eur. Clin. Respir. J."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2018.06.004_bb0875","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.1007\/s10545-008-0930-x","article-title":"Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage","volume":"31","author":"Wang","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0880","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ajmg.a.31600","article-title":"Pulmonary manifestations of Fabry disease and positive response to enzyme replacement therapy","volume":"143","author":"Kim","year":"2007","journal-title":"Am. J. Med. Genet. Part A."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0885","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/crj.12446","article-title":"Long time enzyme replacement therapy stabilizes obstructive lung disease and alters peripheral immune cell subsets in Fabry patients","volume":"11","author":"Odler","year":"2017","journal-title":"Clin. Respir. J."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0890","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","article-title":"Quality of life in patients with Fabry disease: a systematic review of the literature","volume":"10","author":"Arends","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0895","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ejim.2014.07.009","article-title":"Delphi consensus on the current clinical and therapeutic knowledge on Anderson-Fabry disease","volume":"25","author":"Concolino","year":"2014","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0900","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","article-title":"Fabry disease in children: agalsidase-beta enzyme replacement therapy","volume":"83","author":"Borgwardt","year":"2013","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0905","doi-asserted-by":"crossref","first-page":"330","DOI":"10.12968\/bjon.2006.15.6.20681","article-title":"Intravenous enzyme replacement therapy: better in home or hospital?","volume":"15","author":"Milligan","year":"2006","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0910","first-page":"2345","article-title":"Home-based infusion therapy \u2013 a feasible approach for chronically ill patients? A new path to provide superior patient care exemplified in Fabry disease","volume":"138","author":"Beck","year":"2013","journal-title":"Dtcsh. Med. Wochenschr."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0915","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","article-title":"The management and treatment of children with Fabry disease: a United States-based perspective","volume":"117","author":"Hopkin","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0920","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0925","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0930","first-page":"S111","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0935","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1750-1172-7-91","article-title":"Safety and pharmacodynamic effects of a pharmacological chaperone on a-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies","volume":"7","author":"Germain","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0940","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1681\/ASN.2013121322","article-title":"Fabry disease: dose matters","volume":"25","author":"Warnock","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0945","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1517\/13543784.11.10.1467","article-title":"Fabry disease: recent advances in enzyme replacement therapy","volume":"11","author":"Germain","year":"2002","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ymgme.2018.06.004_bb0950","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in Fabry disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0955","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.jaci.2017.12.1001","article-title":"Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion","volume":"6","author":"Lenders","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0960","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/GIM.0b013e318170f868","article-title":"Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme","volume":"10","author":"Bodensteiner","year":"2008","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0965","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0970","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","article-title":"Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease","volume":"21","author":"Ashe","year":"2015","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymgme.2018.06.004_bb0975","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejpb.2016.10.016","article-title":"Applications of lipid nanoparticles in gene therapy","volume":"109","author":"Del Pozo-Rodr\u00edguez","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218301872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218301872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:22:46Z","timestamp":1761088966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218301872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":195,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1096719218301872"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.06.004","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European expert consensus statement on therapeutic goals in Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}